Related Experiment Video
Updated: Aug 19, 2025
Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells
Published on: January 6, 2014
Development of a personalized dendritic cell vaccine and single-cell RNA sequencing-guided assessment of its cell
Qingli Li1, Chao Yang1, Huan Tian2
1Departments of Obstetrics & Gynecology and Pediatrics, West China Second University Hospital, Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, Development and Related Diseases of Women and Children Key Laboratory of Sichuan Province, Center of Growth, Metabolism and Aging, College of Life Sciences, State Key Laboratory of Biotherapy and Collaborative Innovation Center of Biotherapy, Sichuan University, Chengdu 610041, Sichuan, China.
Background Aims:
Dendritic cell (DC)-based immunotherapy is a promising approach to treat cancer; however, there is no consensus on the manufacturing processes. Cell type heterogeneity in products manufactured by various methods is understudied and may elicit safety concerns from the regulatory perspective.
Methods:
We characterized the cell type composition of a recently developed DC vaccine, CUD-002, consisting of DCs loaded with mRNA encoding personalized tumor neoantigens (NCT05270720).
Results:
Using single-cell transcriptomic analysis as an unbiased approach, we found that >80% cells in the final product were DCs and the rest primarily comprised myelocytes and lymphocytes. Subsequent fluorescence-activated cell sorting analyses confirmed these cellular identities. These results indicate that unintended cells originate from leukapheresis, the first step of the manufacturing process, and thus likely safe. Consistently, no overt toxicity or tumorigenicity was observed in mice inoculated with CUD-002.
Conclusions:
Considering that leukapheresis is a widely used procedure for collecting diverse peripheral blood cell types to manufacture various cytotherapies, this study establishes a workflow to analyze and address regulatory considerations on cell type heterogeneity.
Insights
This study analyzed the cell composition of a dendritic cell (DC) cancer vaccine, CUD-002. The vaccine primarily contained DCs, with minor amounts of other cells, indicating a safe manufacturing process for DC-based immunotherapy.
Area of Science:
- Immunology
- Cell Biology
- Cancer Therapy
Background:
- Dendritic cell (DC)-based immunotherapy shows promise for cancer treatment.
- Manufacturing processes for DC vaccines lack standardization.
- Cellular heterogeneity in manufactured products raises regulatory and safety concerns.
Purpose of the Study:
- To characterize the cell type composition of the CUD-002 dendritic cell vaccine.
- To assess the safety and origin of cellular heterogeneity in the vaccine product.
- To establish a workflow for analyzing cell type heterogeneity in DC-based therapies.
Main Methods:
- Single-cell transcriptomic analysis was employed for unbiased cell type characterization.
- Fluorescence-activated cell sorting (FACS) was used to confirm cellular identities.
- Pre-clinical safety assessment in mice was conducted.
Main Results:
- >80% of cells in the CUD-002 vaccine product were identified as dendritic cells (DCs).
- The remaining cells primarily consisted of myelocytes and lymphocytes, originating from the leukapheresis process.
- No overt toxicity or tumorigenicity was observed in mice inoculated with the CUD-002 vaccine.
Conclusions:
- The manufacturing process for CUD-002 yields a product with acceptable cellular heterogeneity.
- Leukapheresis is the likely source of non-DC cell types, posing minimal safety risks.
- A validated workflow exists for assessing and addressing regulatory considerations of cell type heterogeneity in DC-based therapies.
